Sodium valproate or valproate semisodium: Is there a difference in the treatment of bipolar disorder?

Psychiatric Bulletin

Volumn 27, Issue 12, 2003, Pages 446-448

  Fisher, Chris ^a   Broderick, Wendy ^a  

^a Earls House Hospital ^*  (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LITHIUM SALT; PLACEBO; VALPROATE SEMISODIUM; VALPROIC ACID; VALPROMIDE;

ARTICLE; BIPOLAR DISORDER; BIPOLAR MANIA; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG COST; DRUG EFFICACY; DRUG TOLERABILITY; DRUG USE; ENTERIC COATED TABLET; GASTROINTESTINAL SYMPTOM; HEALTH CARE COST; HUMAN; LICENSING; MAINTENANCE THERAPY; SIDE EFFECT;

EID: 0346777357     PISSN: 09556036     EISSN: None     Source Type: Journal    
DOI: 10.1192/pb.27.12.446     Document Type: Article

References (22)

1. Bowden, C., Brugger, A., Swann, A., et al. (1994) Efficacy of divalproex vs lithium and placebo in the treatment of mania. JAMA, 271, 918-924.
2. ___, Calabrese, J., McElroy, S., et al. (2000) A randomised placebo controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Archives of General Psychiatry, 57, 481-489.
3. Brasfield, K. (1999) Pilot study of divalproex sodium versus valproic acid drug acquisition costs versus all related costs. Current Therapeutic Research, 60, 138-144.
4. Brown, C., Wang, J. & Young, L. (2000) Increased expression of endoplasmic reticulum stress proteins following chronic valproate treatment of rat glioma cells. Neuropharmacology, 39, 2162-2169.
5. Davis, L., Ryan, W., Adinoff, B., et al. (2000) Comprehensive review of the psychiatric uses of valproate. Journal of Clinical Psychopharmacology, 20, (suppl. 1), 1-17s.
6. Demoulin, L. & Landry, P. (2000) Plasma concentration of valproate following substitution of divalproex sodium by valproic acid. Canadian Journal of Psychiatry, 45, 761.
7. Department of Health (2002) Drug Tariff, January 2002. London: DoH.
8. Douglas-Hall, P., Fuller, A. & Gill-Banham, S. (2001) An analysis of off-licence prescribing in psychiatric medicine. Pharmaceutical Journal, 267, 890-891.
9. Food and Drug Administration (2002) Depakote® tablets. http://www.accessdata.fda.gov/scripts/cder/ob/docs/temptn.cfm.
10. Freeman, T., Clothier, J., Pazzaglia, P., et al. (1992) A double blind comparison of valproate in the treatment of acute mania. American Journal of Psychiatry, 149, 108-111.
11. Lambert, P. & Venaud, G. (1992) Etude comparative du valpromide versus lithium dans la prophylaxie des troubles thymiques. Nervure, 5, 57-65.
12. Macritchie, K., Geddes, J., Scott, J., et al. (2001) Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder (Cochrane Review). Cochrane Library, issue 4. Oxford: Update Software.
13. MIMS (2002) Monthly Index of Medical Specialities, January. London: Haymarket.
14. Perry, P., Bever-Stille, K., Arndt, S., et al. (2000) Correlation of valproate plasma concentrations and dose in bipolar affective disorder. Journal of Clinical Psychopharmacology, 20, 277-279.
15. Perucca, E. (2002) Pharmacological and therapeutic properties of valproate: A summary after 35 years of clinical experience. CNS Drugs, 16, 695-714.
16. Pope, H., McElroy, S., Keck, P., et al. (1991) Valproate in the treatment of acute media: A placebo controlled study. Archives of General Psychiatry, 46, 62-68.
17. Roberts, D., Easter, D. & O'Bryan-Tear, G. (1996) Epilim Chrono: A multidose crossover comparison of two formulations of valproate in healthy volunteers. Biopharmaceutics and Drug Disposition, 17, 175-182.
18. Sanofi-Synthelabo (2001) Summary of product characteristics - Depakote®. January 2001. http://www.sanofi-synthelabo.co.uk.
19. Taylor, D., McConnell, H., Duncan-McConnell, D. et al. (2001) The Maudsley Prescribing Guidelines (6th edn). London: Martin Dunitz.
20. Watson, D., Watterson, J. & Lennox, R. (1998) Sodium valproate down-regulates the myristoylated alanine-rich C kinase substrate (MARCKS) in immortalised hippocampal cells: A property of protein kinase C-mediated mood stabilisers. Journal of Pharmacology and Experimental Therapeutics, 285, 307-316.
21. Zaccara, G., Messori, A. & Moroni, F. (1988) Clinical pharmacokinetics of valproic acid - 1988. Clinical Pharmacokinetics, 15, 367-389.
22. Zarate, C., Tohen, M., Narendran, R., et al. (1999) The adverse effect profile and efficacy of divalproex sodium compared with valproic acid: A pharmacoepidemiology study. Journal of Clinical Psychiatry, 60, 232-236.